| Comparison of E-health vs. In-person Multi-Family Group (MFG) (NCT02032680) | VA Office of Research and Development | 2015-08-19 |
| Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders (NCT02930005) | The University of Texas Health Science Center, Houston | 2015-08-07 |
| Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia (NCT02469389) | VA Office of Research and Development | 2015-08-03 |
| Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms (NCT02529163) | Centre for Addiction and Mental Health | 2015-08-01 |
| Study of Immunotherapy in Autoantibody Positive Psychosis (NCT02449746) | University of Cambridge | 2015-08-01 |
| Nicotinic Receptors and Schizophrenia (NCT02538081) | VA Office of Research and Development | 2015-08-01 |
| Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) (NCT02600741) | Janssen Scientific Affairs, LLC | 2015-07-24 |
| A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (NCT02431702) | Janssen Scientific Affairs, LLC | 2015-07-08 |
| Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate (NCT02532842) | Janssen Pharmaceutica N.V., Belgium | 2015-07-01 |
| Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN) (NCT02404155) | University of Maryland, Baltimore | 2015-07-01 |
| A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia (NCT02477020) | Takeda | 2015-07-01 |
| A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics (NCT02712463) | Janssen-Cilag Ltd. | 2015-07-01 |
| Building Employment Skills Through Therapy for Veterans (NCT01992913) | VA Office of Research and Development | 2015-06-12 |
| A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment (NCT02469155) | Intra-Cellular Therapies, Inc. | 2015-06-01 |
| The Music Study in Refractory Psychosis (NCT02431949) | University of British Columbia | 2015-06-01 |
| Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness (NCT02421965) | Dartmouth-Hitchcock Medical Center | 2015-06-01 |
| Prepulse Inhibition (PPI) of Startle Reflex in Schizophrenia Patients Related to Type of Treatment and Illness Duration (NCT02484521) | HaEmek Medical Center, Israel | 2015-06-01 |
| In Vivo Imaging of Therapeutic Electric Current Flow (NCT02453763) | University of Florida | 2015-06-01 |
| OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant (NCT02415764) | Center for Social Innovation, Massachusetts | 2015-06-01 |
| Efficiency of Art-therapy in Psychotic Disorders (NCT02383095) | University Hospital, Strasbourg, France | 2015-05-27 |
| The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong (NCT02435784) | The University of Hong Kong | 2015-05-01 |
| Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse (NCT03558529) | Manchester Academic Health Science Centre | 2015-05-01 |
| A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia (NCT02164981) | Massachusetts General Hospital | 2015-05-01 |
| The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism (NCT02552758) | Shanghai Mental Health Center | 2015-05-01 |
| Antipsychotic Induced Structural and Functional Brain Changes (NCT02435095) | RWTH Aachen University | 2015-05-01 |
| STimulation to Improve Auditory haLLucinations (NCT02360228) | University of North Carolina, Chapel Hill | 2015-05-01 |
| Exercise and Cognitive Training (NCT02326389) | Boston University Charles River Campus | 2015-05-01 |
| A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry (NCT02462473) | Janssen Research & Development, LLC | 2015-05-01 |
| Mindfulness Group-based Intervention for Early Psychosis: A Pilot Study (NCT02342210) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2015-05-01 |
| Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers (NCT02392468) | Boehringer Ingelheim | 2015-04-15 |
| Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination (NCT02426983) | University of Ottawa | 2015-04-01 |
| A Pharmacokinetic Study of Paliperidone ER (NCT02433717) | National Taiwan University Hospital | 2015-04-01 |
| A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia (NCT02418819) | Pfizer | 2015-04-01 |
| A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia (NCT01952041) | Dartmouth-Hitchcock Medical Center | 2015-03-13 |
| Linagliptin and Mesenchymal Stem Cells: A Pilot Study (NCT02442817) | University of Nevada, Reno | 2015-03-02 |
| Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia (NCT00356317) | University of Miami | 2015-03-01 |
| Integrated Coping and Awareness Training (NCT02400502) | University of North Carolina, Chapel Hill | 2015-03-01 |
| Evaluation of Social Skills Intervention on Cognitive Function in Schizophrenia (NCT02134418) | Clalit Health Services | 2015-03-01 |
| Retinoic Acid Homeostasis in Neuropsychiatric Diseases (NCT02439099) | Charite University, Berlin, Germany | 2015-03-01 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia (NCT02411695) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2015-03-01 |
| Treatment of Social Cognition in Schizophrenia Trial (NCT02246426) | Posit Science Corporation | 2015-03-01 |
| Researching the Effectiveness of Acceptance-Based Coping During Hospitalization (NCT02336581) | Butler Hospital | 2015-03-01 |
| Task Sharing for the Care of Severe Mental Disorders in a Low-income Country (NCT02308956) | University of Cape Town | 2015-03-01 |
| Biological Implications of the Overlapping Phenomenon Between Childhood Schizophrenia and Autism Spectrum Disorders-Heterogeneity Approach Rather Than Diagnostic Boundary (NCT06063525) | National Taiwan University Hospital | 2015-02-02 |
| Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (NCT02307396) | Technical University of Munich | 2015-02-01 |
| Clinical Registry of Patients Under Treatment With Atypical Antipsychotics (NCT02409823) | Pontifical Catholic University of Argentina | 2015-02-01 |
| A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis (NCT02398292) | Oregon Health and Science University | 2015-02-01 |
| Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia (NCT02197286) | NYU Langone Health | 2015-02-01 |
| Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia (NCT02411526) | Zogenix, Inc. | 2015-02-01 |
| European Long-acting Antipsychotics in Schizophrenia Trial (NCT02146547) | UMC Utrecht | 2015-02-01 |
| Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients (NCT02188121) | Mclean Hospital | 2015-02-01 |
| Minocycline Augmentation to Clozapine (NCT02124811) | Emory University | 2015-02-01 |
| Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia (NCT02332798) | Biogen | 2015-01-06 |
| Study of the Effect of Dosing on Clozapine Levels (NCT02286206) | University of British Columbia | 2015-01-01 |
| Pharmacovigilance in Gerontopsychiatric Patients (NCT02374567) | Hannover Medical School | 2015-01-01 |
| Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes (NCT02188732) | Dartmouth-Hitchcock Medical Center | 2015-01-01 |
| Berberine Treat Metabolic Syndrome in Schizophrenia (NCT03251716) | Tianjin Anding Hospital | 2015-01-01 |
| Minocycline add-on to Antipsychotics for the Treatment of Negative and Cognitive Symptoms in Schizophrenia (NCT02907437) | Beer Yaakov - Ness Ziona Mental Health Center | 2015-01-01 |
| Transcranial Direct Current Stimulation Influences on Cognitive Inhibition in Schizophrenia (NCT01971073) | Bar-Ilan University, Israel | 2015-01-01 |
| Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up (NCT03883204) | Fundación Marques de Valdecilla | 2015-01-01 |
| Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia (NCT02069392) | University of Maryland, Baltimore | 2015-01-01 |
| An Evaluation of a Psychoeducation Program in Individuals Diagnosed With Schizophrenia (NCT03865186) | Kırıkkale University | 2015-01-01 |
| Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia (NCT02205437) | Fundación Marques de Valdecilla | 2015-01-01 |
| Transcranial Direct Current Stimulation (TDCS) for Auditory Hallucinations in Early Onset Schizophrenia (EOS) (NCT02764164) | Children's Hospital Medical Center, Cincinnati | 2015-01-01 |
| Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700 (NCT02333487) | H. Lundbeck A/S | 2014-12-30 |
| Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics (NCT02360319) | Vanguard Research Group | 2014-12-11 |
| Joint Crisis Plan Effectiveness in Preventing Relapses in Schizophrenia and Schizoaffective Disorder (NCT02627716) | University Hospital, Lille | 2014-12-05 |
| Brain Imaging, Attention, and Auditory Processing in Schizophrenia (NCT03068806) | San Francisco Veterans Affairs Medical Center | 2014-12-01 |
| Long-term Study of DSP-5423P in Patients With Schizophrenia (NCT02335658) | Sumitomo Pharma Co., Ltd. | 2014-12-01 |
| Confirmatory Study of DSP-5423P in Patients With Schizophrenia (NCT02287584) | Sumitomo Pharma Co., Ltd. | 2014-12-01 |
| Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia (NCT02282085) | Matt Byerly | 2014-12-01 |
| An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia (NCT02320032) | Alkermes, Inc. | 2014-12-01 |
| Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects (NCT02331433) | CoMentis | 2014-12-01 |
| Characterization of the Motivational Deficit in Schizophrenia and Depression (NCT02378818) | Centre Hospitalier St Anne | 2014-11-21 |
| Immuno-Genetic, Inflammation, Retro-Virus, Environment (NCT02878408) | Pr. Marion Leboyer | 2014-11-07 |
| Schizophrenia TreAtment With electRic Transcranial Stimulation (NCT02535676) | University of Sao Paulo | 2014-11-01 |
| A Trial to Assess the Antipsychotic Efficacy of ITI-007 (NCT02282761) | Intra-Cellular Therapies, Inc. | 2014-11-01 |
| Effectiveness of the RemedRugby Program (NCT03775564) | Hospital Center Alpes-Isère | 2014-11-01 |
| The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain (NCT02281162) | Creighton University | 2014-11-01 |
| Compensatory Cognitive Training in Clinical High Risk Latino Youth (NCT02245607) | University of California, San Diego | 2014-10-01 |
| DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia (NCT02532686) | China Medical University Hospital | 2014-10-01 |
| Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia (NCT02288845) | Intra-Cellular Therapies, Inc. | 2014-10-01 |
| Improving Cognition in Schizophrenia Using tDCS (NCT02539797) | University of California, Los Angeles | 2014-10-01 |
| Efficiency of the French Translation Social Cognition and Interactive Training (SCIT)Program (NCT02667834) | Hôpital le Vinatier | 2014-10-01 |
| Electronic Cigarettes in Smokers With Mental Illness (NCT02212041) | King's College London | 2014-09-24 |
| Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia (NCT06387771) | Clinica Universidad de Navarra, Universidad de Navarra | 2014-09-22 |
| Connectomics in Psychiatric Classification of Bipolar Disorder and Schizophrenia (NCT02756065) | Washington University Early Recognition Center | 2014-09-01 |
| Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia (NCT02234752) | Sheppard Pratt Health System | 2014-09-01 |
| Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia (NCT02417142) | University of Massachusetts, Worcester | 2014-09-01 |
| Multicentre Evaluation of Bucco-dental Health in Patients With Schizophrenia in Côte d'Or (NCT02167724) | Centre Hospitalier Universitaire Dijon | 2014-09-01 |
| Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs (NCT02986490) | University Hospital, Montpellier | 2014-09-01 |
| Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (NCT02237417) | University of Utah | 2014-09-01 |
| Psychoeducation for Vietnamese Families With a Patient With Schizophrenia (NCT02715349) | Danang Psychiatric Hospital | 2014-09-01 |
| Pharmacokinetic Study of MIN-101 in Healthy Subjects (NCT02232529) | Minerva Neurosciences | 2014-09-01 |
| Longitudinal Long-term Study (10 Years) of the Sample of First Episode of Non-affective Psychosis: PAFIP (NCT02200588) | Fundación Marques de Valdecilla | 2014-09-01 |
| Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations (NCT04296604) | Massachusetts General Hospital | 2014-09-01 |
| Bioavailability of LY03004 and Risperdal® Consta® (NCT02091388) | Luye Pharma Group Ltd. | 2014-09-01 |
| Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity (NCT02118610) | University of Maryland, Baltimore | 2014-09-01 |
| Tryptophan MRI in People With Schizophrenia and Healthy Controls (NCT02067975) | University of Maryland, Baltimore | 2014-08-14 |
| Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia (NCT02874560) | Janssen-Cilag Ltd. | 2014-08-12 |